Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Riluzole
Drug ID BADD_D01942
Description A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.
Indications and Usage For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)
Marketing Status approved; investigational
ATC Code N07XX02
DrugBank ID DB00740
KEGG ID D00775
MeSH ID D019782
PubChem ID 5070
TTD Drug ID D0H0KB
NDC Product Code 68462-381; 70510-2201; 42291-775; 0378-4145; 62756-538; 67877-286; 69076-200; 63278-1076; 65129-1011; 70515-700; 65977-0045; 66039-812
UNII 7LJ087RS6F
Synonyms Riluzole | 2-Amino-6-trifluoromethoxybenzothiazole | 2 Amino 6 trifluoromethoxybenzothiazole | Rilutek | RP-54274 | RP 54274 | RP54274 | PK-26124 | PK 26124 | PK26124
Chemical Information
Molecular Formula C8H5F3N2OS
CAS Registry Number 1744-22-5
SMILES C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Psychotic disorder19.03.01.002--
Pulmonary function test decreased13.19.01.001--Not Available
Pulmonary toxicity22.01.02.007; 12.03.01.0130.001615%Not Available
Hepatobiliary disease09.01.08.003--Not Available
Urine analysis abnormal13.13.02.008--Not Available
Congenital foot malformation15.11.07.002; 03.11.07.002--Not Available
Vulvovaginal mycotic infection21.14.02.004; 11.03.05.004--Not Available
Liver injury09.01.07.022; 12.01.17.012--Not Available
Adverse reaction08.06.01.018--Not Available
Skin mass23.07.04.014--Not Available
Traumatic liver injury12.01.17.027; 09.01.08.010--Not Available
Anorectal discomfort07.03.03.003--Not Available
Gastrointestinal tract irritation07.08.03.008--Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.0230.000538%Not Available
Candida infection11.03.03.021--
Mesenteric vascular occlusion24.04.08.014; 07.15.02.011--Not Available
Respiratory symptom22.12.02.0130.000538%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000808%
Anal incontinence17.05.01.021; 07.01.06.029--
Depersonalisation/derealisation disorder19.14.01.004--Not Available
Pancreatitis relapsing07.18.01.0110.001346%Not Available
Pseudarthrosis15.08.01.001; 12.04.02.0100.000538%Not Available
Haemorrhagic necrotic pancreatitis24.07.02.047; 07.18.01.0100.000538%Not Available
Cervical spinal cord paralysis17.01.04.0220.000538%Not Available
Dilated cardiomyopathy02.04.01.017--Not Available
Hypersensitivity pneumonitis10.01.03.056; 22.01.01.027--Not Available
Intermenstrual bleeding21.01.01.015--Not Available
Progressive bulbar palsy17.05.05.0050.000538%Not Available
The 14th Page    First    Pre   14    Total 14 Pages